跳至主要内容
临床试验/EUCTR2015-005090-20-IT
EUCTR2015-005090-20-IT进行中(未招募)1 期

Rivaroxaban or placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer: a randomized, double blind, placebo-controlled study. THE PRO-LAPS STUDY II - The PROLAPS II Study

FONDAZIONE FADOI0 个研究点目标入组 646 人开始时间: 2021年6月17日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
646

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - Objective diagnosis of Colorectal Cancer
  • - Elective laparoscopic surgery for colorectal cancer
  • - Whatever the stage of cancer
  • - Antithrombotic prophylaxis with LMWH administered for 7±2 days after surgery
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 200
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 446

排除标准

  • - age < 18 years
  • - surgery for non-cancer disease
  • - duration of surgery < 45 min
  • - Conversion to open surgery
  • - other indication for anticoagulant therapy
  • - known cerebral metastases
  • - kidney or liver failure
  • - known hemorrhagic diathesis or high risk for bleeding
  • - history of intracerebral bleeding or neurosurgery within 6 months, history of heparin induced thrombocytopenia
  • - pregnancy or lactation
  • - refusal of informed consent

研究者

相似试验